EFEKTIVITAS PENAMBAHAN DIACEREIN TERHADAP KADAR INTERLEUKIN-1β DAN KENDALI GLIKEMIK PADA PASIEN DIABETES MELITUS TIPE 2 TIDAK TERKONTROL DI RS MOHAMMAD HOESIN PALEMBANG

SIPAYUNG, MERYLLA FILIANTY and Kusnadi, Yulianto and Legiran, Legiran (2025) EFEKTIVITAS PENAMBAHAN DIACEREIN TERHADAP KADAR INTERLEUKIN-1β DAN KENDALI GLIKEMIK PADA PASIEN DIABETES MELITUS TIPE 2 TIDAK TERKONTROL DI RS MOHAMMAD HOESIN PALEMBANG. Masters thesis, Sriwijaya University.

Preview	Image RAMA_11802_04013782227005_cover.jpg - Accepted Version Available under License Creative Commons Public Domain Dedication. Download (363kB) | Preview
	Text RAMA_11802_04013782227005.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (5MB) | Request a copy
	Text RAMA_11802_04013782227005_TURNITIN.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (14MB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_01_front_ref.pdf - Accepted Version Available under License Creative Commons Public Domain Dedication. Download (1MB)
	Text RAMA_11802_04013782227005_8886210016_0018117201_02.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (2MB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_03.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (666kB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_04.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (822kB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_05.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (662kB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_06.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (222kB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_07_ref.pdf - Bibliography Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (370kB) | Request a copy
	Text RAMA_11802_04013782227005_8886210016_0018117201_08_lamp.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Public Domain Dedication. Download (1MB) | Request a copy

Abstract

Background: Uncontrolled type 2 diabetes mellitus (T2DM) is a major health problem characterized by chronic hyperglycemia and systemic inflammation, where Interleukin-1β (IL-1β) plays a key role in worsening insulin resistance. Diacerein, an IL-1β inhibitor, has shown potential to reduce inflammation and improve glycemic control. This study aimed to assess the efficacy of diacerein on IL-1β levels and glycemic control in uncontrolled T2DM patients. Methods: This double-blind, randomized clinical trial was conducted between July and October 2024 at the Endocrine Metabolic Diabetes Outpatient Clinic of Mohammad Hoesin General Hospital. A total of 34 patients with uncontrolled T2DM were randomized into diacerein (n=17) and placebo (n=17) groups using block-permuted randomization. Patients received either diacerein 50 mg or placebo twice daily for 90 days. Baseline and post-intervention assessments included serum IL-1β, glycated hemoglobin (HbA1c), and fasting blood glucose (FBG). Results: Of the 34 patients enrolled, 4 (2 in each group) dropped out, leaving 30 patients (15 per group) for the final analysis. Baseline characteristics were similar between groups (p>0.05). After 90 days, the diacerein group exhibited a significant reduction in HbA1c (-0.7%; p=0.002) and FBG (-66.47 mg/dL; p=0.004) compared to the placebo group, which showed no significant changes. IL-1β levels demonstrated minimal changes in both groups, with no statistical significance (p>0.05). Multivariate analysis confirmed diacerein as an independent predictor of HbA1c and FBG reduction (p=0.025 and p=0.019, respectively). No severe adverse effects were observed, with only mild gastrointestinal symptoms reported in the diacerein group. Conclusion: The addition of diacerein significantly improved glycemic control (HbA1c and FBG) in uncontrolled T2DM patients, without significant effects on IL-1β levels.

Item Type:	Thesis (Masters)
Uncontrolled Keywords:	Diacerein, Interleukin-1β, Diabetes Mellitus Tipe 2 Tidak Terkontrol
Subjects:	R Medicine > RC Internal medicine > RC648-665 Diseases of the endocrine glands. Clinical endocrinology
Divisions:	04-Faculty of Medicine > 11802-Internal Medicine (Sp
Depositing User:	Merylla Filianty Sipayung
Date Deposited:	12 Mar 2025 04:25
Last Modified:	12 Mar 2025 04:25
URI:	http://repository.unsri.ac.id/id/eprint/168455

Actions (login required)

View Item